How do you approach imetelstat therapy in MDS patients with baseline neutropenia or thrombocytopenia?
1 Answer
Mednet MemberInvited Expert
Hematology · University of Chicago
Answered on
Given the fact that the major treatment-emergent adverse events noted on the phase III IMERGE study in the imetelstat-treated arm were neutropenia (68% Grade 3+ tox) and thrombocytopenia (62% Grade 3+ tox), it makes it somewhat difficult to utilize imetelstat (Platzbecker et al., PMID 38048786) in patients with severe cytopenias beyond anemia. In general, patients should have an ANC > 1.0K and platelet count > 50K prior to each dose of imetelstat. In patients with lower-risk MDS who have severe ...
Join for free or sign in to see the full answer